Fred Reid
AstraZeneca (United Kingdom)(GB)AstraZeneca (Singapore)(SG)AstraZeneca (Switzerland)(CH)AstraZeneca (Poland)(PL)AstraZeneca (Spain)(ES)
Publications by Year
Research Areas
IL-33, ST2, and ILC Pathways, Eosinophilic Esophagitis, Asthma and respiratory diseases, Cystic Fibrosis Research Advances, Immune Cell Function and Interaction
Most-Cited Works
- → A Randomized Phase I Study of the Anti‐Interleukin‐33 Antibody Tozorakimab in Healthy Adults and Patients With Chronic Obstructive Pulmonary Disease(2023)38 cited
- → A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4(2025)36 cited
- → Population pharmacokinetic/target engagement modelling of tozorakimab in healthy volunteers and patients with chronic obstructive pulmonary disease(2024)12 cited
- → A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2(2023)10 cited
- Correlation of 2-PAM plasma levels after organophosphate intoxication.(1985)
- → Late Breaking Abstract - FRONTIER-4: a phase 2a study to investigate tozorakimab (anti-IL-33 mAb) in COPD(2024)3 cited